Ocular Therapeutix, Inc. Announces Pricing of Public Offering of Common Stock

BEDFORD, Mass.--(BUSINESS WIRE)--Jun. 4, 2015--
Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced today the pricing of
an underwritten public offering of 4,000,000 shares of its common stock
at a public offering price of $22.00 per share, before underwriting
discounts. The offering consists of 3,200,000 shares being sold by the
Company and 800,000 shares being sold by certain stockholders of the
Company. In addition, the selling stockholders have granted the
underwriters of the offering an option for a period of 30 days to
purchase up to an additional 600,000 shares of the Company’s common
stock at the public offering price, less the underwriting discount.
Ocular Therapeutix will not receive any proceeds from the sale of shares
by the selling stockholders.

Morgan Stanley, Cowen and Company and RBC Capital Markets are acting as
joint book-running managers for the offering. Nomura and BTIG are acting
as co-managers for the offering.

The offering is expected to close on or about June 10, 2015, subject to
customary closing conditions. A registration statement relating to these
securities was declared effective by the Securities and Exchange
Commission on June 4, 2015.

This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development and commercialization of innovative therapies for diseases
and conditions of the eye using its proprietary hydrogel platform
technology. Ocular Therapeutix’s lead product candidates are in Phase 3
clinical development for post-surgical ocular inflammation and pain, and
Phase 2 clinical development for glaucoma, allergic conjunctivitis and
inflammatory dry eye disease. The Company is also evaluating
sustained-release injectable anti-VEGF drug depots for back-of-the-eye
diseases. Ocular Therapeutix’s first product, ReSure®
Sealant, is FDA-approved to seal corneal incisions following cataract
surgery.

The use of this Site is governed by its Terms of Use. The information contained in this Site is for informational purposes only. It is not a substitute for professional medical advice and should not be used to diagnose or treat any medical or health condition.

The contents of this Site are subject to change without notice. Ocular Therapeutix may modify and/or discontinue operation of all or portions of this Site at any time at its sole discretion without notice, and assumes no responsibility to update this Site. Ocular Therapeutix makes no representations or warranties with respect to the use of this Site or any information obtained herein.